Corcept Therapeutics Inc is a United States-based pharmaceutical company. The Company is involved in the discovery and development of drugs that regulate the effects of cortisol or also known as the stress hormone. Founded on 1998, it has focused its research and clinical development activity on drugs that block the glucocorticoid receptor or GR-II receptor, one of the bodys two receptors of cotrisol. Korlym (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.